Axle Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 59)
Axle Health logo

Axle Health

ChallengerHealthcare

General

Home-based care workforce scheduling platform optimizing clinician routing and visit assignment; AI-powered scheduling to reduce drive time and improve capacity for home health agencies.

AI VisibilityBeta
Overall Score
C59
Category Rank
#133 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
63
Gemini
54

About

Axle Health is a healthcare workforce management and scheduling platform purpose-built for home-based care organizations — home health agencies, hospice providers, and in-home primary care companies — helping them optimize clinician scheduling, reduce drive time, and improve workforce utilization. Founded in 2021 and headquartered in San Francisco, Axle Health addresses the operational complexity of field-based healthcare where scheduling must account for clinician availability, patient location, visit duration, clinical qualifications, and geographic routing simultaneously.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

59
Overall Score
90
#133
Category Rank
#2
77
AI Consensus
83
stable
Trend
stable
59
ChatGPT
92
63
Perplexity
93
54
Gemini
89
57
Claude
96
54
Grok
95

Key Details

Category
General
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.